Safety analysis of high dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 31, Issue 8, 2012, Pages 1771-1774

  Parra Ruiz, J ^a   Duenas Gutierrez C ^b   Tomas Jimenez C ^a,c   P Linares Palomino, J ^a   Garrido Gomez, J ^a   Hernandez Quero J ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b Servicio de Medicina Interna   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; DAPTOMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; MUSCLE DISEASE; MUSCLE TOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; RISK ASSESSMENT; SIDE EFFECT; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTICHOLESTEREMIC AGENTS; CREATINE KINASE; DAPTOMYCIN; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84866383436     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-011-1500-y     Document Type: Article

References (23)

1. Baltz RH (2009) Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr Opin Chem Biol 13 (2):144-151
2. Hobbs JK, Miller K, O'Neill AJ, Chopra I (2008) Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. J Antimicrob Chemother 62(5):1003-1008
3. Figueroa DA, Mangini E, Amodio-Groton M, Vardianos B, Melchert A, Fana C, Wehbeh W, Urban CM, Segal-Maurer S (2009) Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 49(2):177-180
4. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC (2009) Safety and clinical outcomes when utilizing high-dose (> or 08 mg/kg) daptomycin therapy. Ann Pharmacother 43 (7):1211-1219
5. Parra-Ruiz J, Pena-Monje A, Tomas-Jimenez C, Pomares-Mora J, Hernandez-Quero J (2011) Efficacy and safety of high dose (>/08 mg/kg/day) daptomycin. Enferm Infecc Microbiol Clin 29 (6):425-427
6. Wu G, Abraham T, Rapp J, Vastey F, Saad N, Balmir E (2011) Daptomycin: evaluation of a high-dose treatment strategy. Int J Antimicrob Agents 38(3):192-196
7. Katz DE, Lindfield KC, Steenbergen JN, Benziger DP, Blackerby KJ, Knapp AG, Martone WJ (2008) A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract 62(9):1455-1464
8. Sauermann R, Rothenburger M, Graninger W, Joukhadar C (2008) Daptomycin: a review 4 years after first approval. Pharmacology 81(2):79-91 (Pubitemid 351182681)
9. Pai MP, Norenberg JP, Anderson T, Goade DW, Rodvold KA, Telepak RA, Mercier RC (2007) Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother 51(8):2741-2747 (Pubitemid 47206208)
10. Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49(2):71-87
11. Fenton C, Keating GM, Curran MP (2004) Daptomycin. Drugs 64 (4):445-455, discussion 457-448 (Pubitemid 38333658)
12. Odero RO, Cleveland KO, Gelfand MS (2009) Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor. J Antimicrob Chemother 63(6):1299-1300
13. Chang JT, Staffa JA, Parks M, Green L (2004) Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 13(7):417-426 (Pubitemid 38996852)
14. Farnier M (2011) Safety review of combination drugs for hyperlipidemia. Expert Opin Drug Saf 10(3):363-371
15. Kostrominova TY, Hassett CA, Rader EP, Davis C, Larkin LM, Coleman S, Oleson FB, Faulkner JA (2010) Characterization of skeletal muscle effects associated with daptomycin in rats. Muscle Nerve 42(3):385-393
16. Kostrominova TY, Coleman S, Oleson FB, Faulkner JA, Larkin LM (2010) Effect of daptomycin on primary rat muscle cell cultures in vitro. Vitro Cell Dev Biol Anim 46(7):613-618
17. Sirvent P, Mercier J, Lacampagne A (2008) New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol 8(3):333-338
18. Berg ML, Estes L, Enzler MJ (2011) Effect of daptomycin with and without concurrent statin therapy on creatine phosphokinase (CPK) values. Abstract #A-1685, 51st ICAAC, Chicago, September 17-20
19. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL (2010) Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 50 (12):1568-1574
20. Crompton JA, North DS, McConnell SA, Lamp KC (2009) Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry. J Chemother 21(4):414-420
21. Chamberlain RS, Culshaw DL, Donovan BJ, Lamp KC (2009) Daptomycin for the treatment of surgical site infections. Surgery 146(2):316-324
22. Sakoulas G (2009) Clinical outcomes with daptomycin: a postmarketing, real-world evaluation. Clin Microbiol Infect 15(Suppl 6):11-16
23. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF (2011) Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52(3):e18-e55